Tristel PLC
09 August 2006
Tristel plc
Directors' Shareholdings
Tristel plc ('Tristel'), the healthcare business which uses its proprietary
chlorine dioxide chemistry for infection control in hospitals, in water
treatment and the food processing industry, announces that Paul Swinney, Chief
Executive, has sold 174,017 ordinary shares to Peter Stephens, a non-executive
director of Tristel, at a price of 48 pence per share.
Paul Swinney's shareholding in Tristel after the sale is 2,544,969 ordinary
shares (10.68%) and Peter Stephens shareholding is 767,414 ordinary shares
(3.22%).
The share sale constitutes a repayment of a personal loan made to Paul Swinney
by Peter Stephens in August 2005. The loan was used by Paul Swinney to settle
certain tax and national insurance liabilities arising from his exercise of
2,265,475 options upon Tristel's admission to AIM on 1st June 2005.
For further information, please contact:
Tristel plc Parkgreen Communications Ltd
Paul Swinney, Chief Executive Paul McManus
Paul Barnes, Finance Director Tel 020 7493 3716
Tel: 01638 721 500 Mob: 07980 541 893
http://www.tristel.com paul.mcmanus@parkgreenmedia.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.